Skip to main content
SpringerLink
Log in

Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab

  • Clinical Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Colorectal cancer (CRC) is the fourth most common cancer in men and the third in women worldwide. Combinations of 5-fluorouracil (5-FU)/folinic acid (FA) with irinotecan or oxaliplatin form the standard treatment approaches for metastatic disease. The introduction of targeted agents has presented the opportunity to improve on the efficacy of current treatments without exacerbating the associated toxicity. Cetuximab (Erbitux®) is an IgG1 monoclonal antibody (MAb) that specifically targets the epidermal growth factor receptor (EGFR) with high affinity and competitively inhibits endogenous ligand binding. Cetuximab has shown good efficacy in combination with irinotecan in CRC that had previously progressed on irinotecan-based therapy. Cetuximab plus irinotecan and various schedules of 5-FU/FA have shown efficacy in a first-line setting. The activity of cetuximab and oxaliplatin-based regimens is being investigated in both first- and subsequent-line settings. Cetuximab is well tolerated and does not increase the side effect profile of agents it is combined with. Other EGFR inhibitors, including the tyrosine kinase inhibitors, gefitinib and erlotinib, and the MAbs, panitumumab and matuzumab, are also being investigated in a number of solid tumors. The vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, although apparently inactive as a single agent, has demonstrated survival benefits when combined with bolus 5-FU/FA and irinotecan in a first-line setting and with 5-FU/FA and oxaliplatin in the second-line treatment of metastatic CRC. In this paper we discuss the use of targeted therapies in the treatment of metastatic CRC, with a focus on cetuximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. GLOBOCAN (2002) http://www-dep.iarc.fr/

  2. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355:1041–1047

    Article  PubMed  CAS  Google Scholar 

  3. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914

    Article  PubMed  CAS  Google Scholar 

  4. Köhne CH, Van Cutsem E, Wils JA et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865

    Article  PubMed  CAS  Google Scholar 

  5. Glimelius B, Ristamaki R, Kjaer M et al (2002) Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as firstline therapy in advanced colorectal cancer. Ann Oncol 13:1868–1873

    Article  PubMed  CAS  Google Scholar 

  6. Bouzid K, Khalfallah S, Tujakowski J et al (2003) A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 14:1106–1114

    Article  PubMed  CAS  Google Scholar 

  7. Delaunoit T, Goldberg RM, Sargent DJ et al (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101:2170–2176

    Article  PubMed  CAS  Google Scholar 

  8. Goldberg RM, Sargent DJ, Morant RS et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  9. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  PubMed  CAS  Google Scholar 

  10. Patt Y, Lin E, Leibmann J et al (2003) Capecitabine plus irinotecan for chemotherapy naive patients with metastatic colorectal cancer (mCRC): US multicenter phase II trial. Proc Am Soc Clin Oncol 22:281 (Abstract 1130)

    Google Scholar 

  11. Muñoz A, Salut A, Escudero P et al (2003) Irinotecan (CPT-11) and capecitabine (C) as first-line treatment of locally advanced or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 22:317 (Abstract 1271)

    Google Scholar 

  12. Borner MM, Dietrich D, Popescu R et al (2003) A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 22:266 (Abstract 1068)

    Google Scholar 

  13. Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091

    Article  PubMed  CAS  Google Scholar 

  14. Lin E, Skibber J, Eng C et al (2004) Phase II study of capecitabine and radiotherapy plus concomitant boost in patients with locally advanced rectal cancer. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 251)

  15. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  PubMed  CAS  Google Scholar 

  16. Fernandez-Martos C, Aparicio J, Vicent JM et al (2004) Biweekly alternating FOLFOX and FOLFIRI in patients with previously untreated, advanced colorectal cancer (ACC): Updated results. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:261 (Abstract 3563)

    Google Scholar 

  17. Souglakos J, Ziras N, Polyzos A et al (2004) Oxaliplatin (l-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): preliminary results of a multicenter randomized phase III trial. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:253 (Abstract 3532)

    Google Scholar 

  18. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593–1611

    Article  PubMed  CAS  Google Scholar 

  19. Sibilia M, Fleischmann A, Behrens A et al (2000) The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102:211–220

    Article  PubMed  CAS  Google Scholar 

  20. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  PubMed  CAS  Google Scholar 

  21. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ (1996) Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284–1292

    Article  Google Scholar 

  22. Fontanini G, Vignati S, Bigini D et al (1995) Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 2:178–183

    Article  Google Scholar 

  23. Saltz L, Rubin M, Hochster H et al (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a (Abstract 7)

    Google Scholar 

  24. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  25. Goldstein NI, Prewett M, Zuklys K et al (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318

    PubMed  CAS  Google Scholar 

  26. Bandyopadhyay D, Mandal M, Adam L et al (1998) Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273:1568–1573

    Article  PubMed  CAS  Google Scholar 

  27. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166–2174

    PubMed  CAS  Google Scholar 

  28. Prewett MC, Hooper AT, Bassi R et al (2002) Enhanced anti-tumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8:9941003

    Google Scholar 

  29. Bonner JA, Raisch KP, Trummell HQ et al (2000) Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18:47S–53S

    PubMed  CAS  Google Scholar 

  30. Saltz L, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  CAS  Google Scholar 

  31. Erlichman C, Sargent DJ (2004) New treatment options for colorectal cancer. N Engl J Med 351:391–392

    Article  PubMed  CAS  Google Scholar 

  32. Vanhoefer U, Harstrick A, Achterrath W et al (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19:1501–1518

    PubMed  CAS  Google Scholar 

  33. Rothenberg ML, Oza AM, Burger B et al (2003) Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 22:252 (Abstract 2003)

    Google Scholar 

  34. Lenz H-J, Mayer RJ, Mirtsching B et al (2005) Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3536

  35. Adenis A, Aranda Aguilar E, Robin Y-M et al (2005) Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3630

  36. Sobrero A, Scheithauer BW, Maurel J et al (2005) Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomized phase III trial (EPIC). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3580

  37. Rosenberg AH, Loehrer PJ, Needle MN et al (2002) Erbitux® (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21: Abstract 536

  38. Rougier P, Raoul JL, Van Laethem J-L et al (2004) Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:248 (Abstract 3513). Updated information presented at the meeting

    Google Scholar 

  39. Folprecht G, Lutz M, Schoeffski P et al (2004) Cetuximab/ irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 283)

  40. Diaz-Rubio E, Tabernero J, Van Custem E et al (2005) Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition)23: Abstract 3535

  41. Seufferlein T, Dittrich C, Riemann JF et al (2005) A phase I/II study of cetuximab with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3644

  42. Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663–669

    Article  PubMed  CAS  Google Scholar 

  43. Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520

    Article  PubMed  CAS  Google Scholar 

  44. Needle MN (2002) Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29:55–60

    PubMed  CAS  Google Scholar 

  45. Gustafson NF, Saltz L, Cunningham D et al (2004) Safety profile of cetuximab in patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 237)

  46. Cunningham D, Pyrhonen S, James RD et al (1998) Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

    Article  PubMed  CAS  Google Scholar 

  47. Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412

    Article  PubMed  CAS  Google Scholar 

  48. Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176

    Article  PubMed  CAS  Google Scholar 

  49. Herbst RS, LoRusso PM, Purdom M, Ward D (2003) Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 4:366–369

    Article  PubMed  CAS  Google Scholar 

  50. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17:23–28

    Google Scholar 

  51. Cohen EE, Rosen F, Stadler WM et al (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 15:1980–1987

    Article  CAS  Google Scholar 

  52. Clark GM, Perez-Soler R, Siu L et al (2003) Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22:196 (Abstract 786)

    Google Scholar 

  53. Saltz L, Kies M, Abbruzzese JL et al (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204 (Abstract 817)

    Google Scholar 

  54. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705

    Article  PubMed  CAS  Google Scholar 

  55. Mass RD, Fyfe G, Hambleton J et al (2004) Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: a combined analysis. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:274 (Abstract 3616)

    Google Scholar 

  56. Mitchell EP, Alberts SR, Schwartz GK et al (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 169a)

  57. Chen XX, Mooney M, Boron M et al (2004) Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI treatment referral center trial (TRC-0301). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:249 (Abstract 3515)

    Google Scholar 

  58. Hurwitz H, Fehrenbacher L, Cartwright T et al (2004) Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:295 (Abstract 3702)

    Google Scholar 

  59. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  60. Giantonio BJ, Chen HX, Catalano PJ et al (2004) Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:199 (Abstract 3017)

    Google Scholar 

  61. National Cancer Institutes (2004) Bevacizumab combined with oxaliplatin-based chemotherapy prolongs survival for previously treated patients with advanced colorectal cancer. www.nci.nih.gov

  62. Xu JM, Azzariti A, Colucci G, Paradiso A (2003) The effect of gefitinib (IRESSA®, ZD1839) in combination with oxaliplatin is scheduledependent in colon cancer cell lines. Cancer Chemother Pharmacol 52:442–448

    Article  PubMed  CAS  Google Scholar 

  63. Koizumi F, Kanzawa F, Ueda Y et al (2004) Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (IRESSA®) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108:464–472

    Article  PubMed  CAS  Google Scholar 

  64. Williams KJ, Telfer BA, Stratford IJ, Wedge SR (2002) ZD1839 (IRESSA®), a specific oral epidermal growth factor receptor-tyrosi-ne kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157-1161

    Article  PubMed  CAS  Google Scholar 

  65. Ranson M (2002) ZD1839 (IRESSA®): for more than just non-small cell lung cancer. Oncologist 7(Suppl 4):16–24

    Article  PubMed  CAS  Google Scholar 

  66. Seymour L, Goss G, Stewart D et al (2002) A translational research study of ZD1839 at a dose of 750 mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann Oncol 13: Abstract 264PD

  67. Rothenberg ML, Lafleur B, Washington MK et al (2004) Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): An Eastern Cooperative Oncology Group study. J Clin Oncol, Annual Meeting Proceedings (Post-Meeting Edition) 22:195 (Abstract 3000)

    Google Scholar 

  68. Townsley C, Major P, Siu LL et al (2004) Phase II study of OSI-774 in patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 222)

  69. Messersmith WA, Laheru DA, Senzer NN et al (2004) Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522–6527

    Article  PubMed  CAS  Google Scholar 

  70. Fisher GA, Kuo T, Cho CD et al (2004) A phase II study of gefitinib in combination with FOLFOX4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:249 (Abstract 3514)

    Google Scholar 

  71. Delord JP, Beale P, Van Custem E et al (2004) A phase Ib dose-escalation trial of erlotinib, capecitabine, and oxaliplatin in metastatic colorectal cancer (MCRC) patients. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:266 (Abstract 3585)

    Google Scholar 

  72. Tejpar S, Van Cutsem E, Gamelin E et al (2004) Phase I/iia study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:265 (Abstract 3579)

    Google Scholar 

  73. Hecht JR, Patnaik A, Malik I et al (2004) ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mcrc): An updated analysis. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:248 (Abstract 3511)

    Google Scholar 

  74. Berlin J, Malik I, Picus J et al (2004) Panitumumab therapy with irinotecan, 5-fluorouracil and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mcrc). Ann Oncol 15: Abstract 265PD

  75. Kim T (2004) Technology evaluation: Matuzumab, Merck kgaa. Curr Opin Mol Ther 6:96–103

    PubMed  CAS  Google Scholar 

  76. Trarbach T, Beyer T, Schleucher N et al (2004) A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:199 (Abstract 3018)

    Google Scholar 

  77. Salazar R, Tabernero J, Rojo F et al (2004) Dose-dependent inhibition of the EGFR and signaling pathways with the anti-EGFR monoclonal antibody (mab) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:127 (Abstract 2002)

    Google Scholar 

  78. Matar P, Rojo F, Cassia R et al (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:64876501

    Article  Google Scholar 

  79. Fischel JL, Formento P, Milano G (2005) Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (IRESSA®) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer 92:1063–1068

    Article  PubMed  CAS  Google Scholar 

  80. Saltz L, Lenz H-J, Hochster H et al (2005) Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuxi-mab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3508

  81. Saltz L, Lenz H, Hochster H et al (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 169b)

  82. Meropol NJ (2005) Epidermal growth factor receptor inhibitors in colorectal cancer: it’s time to get back on target. J Clin Oncol 23:17911793

    Article  CAS  Google Scholar 

  83. Mirtsching BC, Cichon J, Beasley S et al (2005) Cetuximab in refractory metastatic colorectal cancer: Analysis of efficacy and response by patient and disease variables. ASCO Gastrointestinal Cancers Symposium www.asco.org (Abstract 205)

  84. Pippas AW, Lenz H-J, Mayer RJ et al (2005) Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23: Abstract 3595

  85. Lenz HJ, Mayer RJ, Gold PJ et al (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:248 (Abstract 3510)

    Google Scholar 

  86. Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810

    Article  PubMed  CAS  Google Scholar 

  87. Dei Tos AP, Ellis I (2005) Assessing Epidermal Growth Factor Receptor expression in tumors: what is the value of current test methods? Eur J Cancer 41:1383–1392

    Article  PubMed  CAS  Google Scholar 

  88. Younes M (2005) Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy? J Clin Oncol 23:923. Reply: Saltz L, 923–924

    Article  PubMed  Google Scholar 

  89. Atkins D, Reiffen KA, Tegtmeier CL et al (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52:893–901

    Article  PubMed  CAS  Google Scholar 

  90. Sinicrope FA, Half E, Dannenberg K, Wang X (2002) Expression levels of TS, DPD, EGFR and HER2 mrna in primary colorectal cancers and their corresponding metastases. Proc Am Soc Clin Oncol 21:Abstract 2987

  91. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346

    Article  PubMed  CAS  Google Scholar 

  92. Mckay JA, Murray LJ, Curran S et al (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer 38:2258–2264

    Article  PubMed  CAS  Google Scholar 

  93. Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22:4772–4778

    Article  PubMed  CAS  Google Scholar 

  94. Shia J, Klimstra DS, Li AR et al (2005) Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18:1350–1356

    Article  PubMed  CAS  Google Scholar 

  95. Vallbohmer D, Zhang W, Gordon M et al (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536–3544

    Article  PubMed  CAS  Google Scholar 

  96. Personeni N, Hendlisz A, Galdon MG et al (2004) Expression of the activated/phosphorylated epidermal growth factor receptor (EGFR) and downstream effectors, as markers predicting the response to cetuximab (C225) alone or in combination with irinotecan (CPT-11) in EGFR-positive metastatic colorectal cancer (mcrc) refractory to CPT-11. Ann Oncol 15(Suppl 3): Abstract 267PD

  97. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  98. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  99. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Gasthuisberg Herestraat, 49, 3000, Leuven, Belgium

    E. Van Cutsem

  2. Ospedali Riuniti Largo Barozzi, 24128, 1, Bergamo, Italy

    R. Labianca

  3. Istituto Regina Elena Via Chianesi Elio, 53, 00144, Rome, Italy

    F. Cognetti

  4. Vall d’Hebron University, Hospital Passeig de la Vall d’Hebron, 119–29, 08035, Barcelona, Spain

    J. Tabernero

Authors
  1. E. Van Cutsem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Labianca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Cognetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Tabernero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Van Cutsem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Cutsem, E., Labianca, R., Cognetti, F. et al. Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. Targ Oncol 1, 2–12 (2006). https://doi.org/10.1007/s11523-005-0001-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-005-0001-2

Keywords

Search

Navigation